The stock market has been changing this year due to macroeconomic and geopolitical factors. Many of the world's largest companies have not escaped selling, and it's hard to predict the next step. Even so, Wall Street has high hopes for some companies. take Verve Therapeutics (Nasdaq: Vervi)clinical stage biotechnology. According to drugmakers’ average price target of $24.43 (according to Yahoo! Finance), the stock could surge 321% over the next 12 months. This isn't unheard of in the exciting biotech industry, but before rushing to buy Verve Therapeutics' stock, it's the company that investors need to know.
There may be significant value increase in biotech stocks in clinical stages due to promising clinical or regulatory news. If Verve Therapeutics has a chance to soar more than 300% next year, the company will have to impress the market with its leading candidate Verve-102. The product has not been approved yet, but can sufficient progress be made to meet the street estimate? Notably, Verve Therapeutics recently announced positive results for the Phase 1B clinical trial of Verve-102, a potential treatment for heterozygous familial hypercholesterolemia (HEFH) and/or premature coronary disease.
Where to invest $1,000 now? Our team of analysts just revealed what they think is 10 Best Stocks Buy it now. continue"
HEFH is a genetic disease that causes increased levels of LDL cholesterol (LDL-C) - also known as "poor" cholesterol - at high concentrations, it can cause serious cardiovascular problems. During the study period, a single injection of Verve-102 in vivo gene editing therapy resulted in a 53% reduction in the average LDL-C in patients. The drug also showed reasonable safety. These results look promising, especially when considering the potential target market for Verve-102. Verve Therapeutics estimates that in the United States and the EU in HEFH, there are about 3 million patients, and 31 million worldwide.
Despite treatment courses, they usually focus on reducing LDL-C levels. Verve-102 can solve the problem at its source by simply infusion - the choice of a one-time cure may be a game changer in the field. In other words, it will take some time for Verve-102 to be approved. Verve Therapeutics plans to start the second phase in the second half of the year. Furthermore, it may still experience clinical and regulatory setbacks. For all these reasons (and more), Verve Therapeutics' recent clinical success "only" caused the stock price to rise 24% in a day.
Verve Therapeutics is unlikely to see its share price double-not to mention four times next year. Verve-102 won't make any more progress during this period, and its other candidates who are still in early research are unlikely to have a greater impact on its stock performance than its leading program. Still, that doesn't mean that stocks aren't a good investment. Should investors consider adding the stock of gene editing experts to their portfolio?
Like most clinical-stage biotech companies, Verve Therapeutics is too risky for most investors, at least not worth it, at least not hassle. Yes, it has the support of the drug giant. Lily, It cooperates with it to develop Verve-102. This makes Verve Therapeutics less likely to encounter funding problems, which could seriously damage the prospects of small drugmakers. Indeed, Verve Therapeutics’ approach could set new standards of care for HEFH and some related cardiovascular diseases.
Even so, assuming that Verve-102 starts its 3-stage research, it will take at least a few years, assuming everything is done with the company's expectations. If Verve Therapeutics encounters significant resistance with its leading program, investors may have (almost) worthless shares. Therefore, although stocks have huge upward potential, as long as everything goes according to plan, there are sufficient downside risks. Despite the high expectations of Wall Street, risk-averse investors should watch this observation now, but should be unfolding from the off-market for the moment.
Before you purchase inventory for Verve Therapeutics, consider the following:
this Motley Fool Stock Advisor The analyst team just confirmed what they think is 10 Best Stocks Investors buy now…and Verve Therapeutics is not one of them. Ten stocks with layoffs could generate monster returns in the coming years.
When to consider Netflix On this list on December 17, 2004...If you invested $1,000 when you suggested, You will have $594,046! * Or when Nvidia This list was listed on April 15, 2005...If you invested $1,000 when you suggested, You will have $680,390! *
Now, it's worth noting Stock ConsultantThe overall average return is 872% - Compared to market sprints 160% For the S&P 500 index. Don't miss the latest top ten list, available when you join Stock Consultant.
View 10 stocks »
*Stock consultant returns as of April 28, 2025
Prosper Junior Bakiny has a position at Eli Lilly. Motley fool has no position in any stock mentioned. Motley Fool has a disclosure policy.
According to Wall Street, the stock that 1 person was hit was originally published by Motley Fool